As we approach imminent data results on the clinical phase 1...

As we approach imminent data results on the clinical phase 1 breast cancer, a couple of thoughts.
This trail will give us a between groups comparison. That is, 3 levels of PTX-200 escalation to current level.
Keys criteria include, toxicity levels held below significant, potency increase and of course overall efficiency escalation between groups.
At this stage, and pending above findings, if results are favourable, we may even see a similar design to the concurrent AML trail whereby further design of optimising dosage levels takes place pre/or in phase 2.
Patience during trails (that's why they are called as such) is essential.
Exciting times ahead.